sunitinib pharmascience 37,5 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba u obliku sunitinibklorida
sunitinib pharmascience 50 mg tvrde kapsule
pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba u obliku sunitinibklorida
pazopanib pharmascience 200 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 200 mg pazopaniba u obliku pazopanibklorida
pazopanib pharmascience 400 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 400 mg pazopaniba u obliku pazopanibklorida
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
enalapril/lerkanidipin pharmaswiss 10/10 mg filmom obložene tablete
pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - enalaprilum, lercanidipinum - filmom obložena tableta - 10 mg + 10 mg - urbroj: jedna tableta sadrži 10 mg enalaprilmaleata i 10 mg lerkanidipinklorida
enalapril/lerkanidipin pharmaswiss 20/10 mg filmom obložene tablete
pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - enalaprilum, lercanidipinum - filmom obložena tableta - 20 mg + 10 mg - urbroj: jedna tableta sadrži 20 mg enalaprilmaleata i 10 mg lerkanidipinklorida
sorafenib pharmascience 200 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - sorafenibtosilat - filmom obložena tableta - 200 mg - urbroj: svaka filmom obložena tableta sadrži 200 mg sorafeniba (u obliku tosilata).
deferasiroks pharmascience 180 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 180 mg deferasiroksa
deferasiroks pharmascience 360 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 360 mg deferasiroksa